Comparing two treatments for recurrent ovarian cancer after PARP inhibitor therapy
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial compares a combination of two drugs (sacituzumab govitecan and bevacizumab) to standard chemotherapy for ovarian cancer that has come back after treatment with a PARP inhibitor. It is for people whose cancer has a BRCA mutation or is homologous recombination deficient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-grade serous or endometrioid ovarian cancer, which includes fallopian tube or primary peritoneal cancer.
- Your cancer responded to platinum-based chemotherapy for at least 6 months before coming back.
- Your cancer got worse while you were on your first maintenance PARP inhibitor treatment (like Olaparib or Niraparib).
- Your tumor has a BRCA1 or BRCA2 mutation (inherited or found in the tumor) or is positive for homologous recombination deficiency (HRD).
- You have not had any treatment with a topoisomerase-I inhibitor before (like irinotecan or topotecan).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (sacituzumab tirumotecan and bevacizumab) for women whose ovarian cancer stopped responding to platinum chemotherapy. The goal is to see if the combination helps shrink or slow the cancer.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
This Phase 2 trial compares two standard doses of bevacizumab (a medicine that targets blood supply to tumors) added to chemotherapy in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. It’s for ovarian cancers that have returned or grown again soon after prior platinum chemotherapy, with the goal of improving control of the disease.
This trial tests a new drug called mocertatug rezetecan combined with bevacizumab against standard platinum chemo plus bevacizumab. It's for women with ovarian cancer that came back after treatment and is still sensitive to platinum drugs.
Hear when a new Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.